Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on Olema Pharmaceuticals. The associated price target remains the same with $27.00.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sam Slutsky’s rating is based on Olema Pharmaceuticals’ promising development pipeline, particularly their work on palazestrant (OP-1250), a complete estrogen receptor antagonist and selective estrogen receptor degrader. The company is advancing this compound in the treatment of advanced/metastatic ER+ breast cancer, and there are potential positive implications from upcoming data expected from Roche and AstraZeneca trials in the same treatment space.
Slutsky notes that Olema’s ongoing Phase 3 OPERA-02 study, which tests palazestrant in combination with ribociclib, could benefit from favorable progression-free survival outcomes. Additionally, Olema’s use of a more active CDK4/6 inhibitor and higher drug exposure levels could position their treatment as a competitive option. These factors contribute to the optimistic outlook and the Buy rating for Olema’s stock.
In another report released on November 11, Oppenheimer also reiterated a Buy rating on the stock with a $22.00 price target.